CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We have now added a new section called the "Assay History List" to the "At A Gla...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...